These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 21659785)

  • 1. Phase II study of combined treatment with irinotecan and S-1 (IRIS) in patients with inoperable or recurrent advanced colorectal cancer (HGCSG0302).
    Komatsu Y; Yuki S; Sogabe S; Fukushima H; Iwanaga I; Kudo M; Tateyama M; Meguro T; Uebayashi M; Saga A; Sakata Y; Asaka M
    Oncology; 2011; 80(1-2):70-5. PubMed ID: 21659785
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II study of combined chemotherapy with irinotecan and S-1 (IRIS) plus bevacizumab in patients with inoperable recurrent or advanced colorectal cancer.
    Komatsu Y; Yuki S; Sogabe S; Fukushima H; Nakatsumi H; Kobayashi Y; Iwanaga I; Nakamura M; Hatanaka K; Miyagishima T; Kudo M; Munakata M; Meguro T; Tateyama M; Sakata Y
    Acta Oncol; 2012 Sep; 51(7):867-72. PubMed ID: 22554343
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomised phase 2/3 non-inferiority study (FIRIS study).
    Muro K; Boku N; Shimada Y; Tsuji A; Sameshima S; Baba H; Satoh T; Denda T; Ina K; Nishina T; Yamaguchi K; Takiuchi H; Esaki T; Tokunaga S; Kuwano H; Komatsu Y; Watanabe M; Hyodo I; Morita S; Sugihara K
    Lancet Oncol; 2010 Sep; 11(9):853-60. PubMed ID: 20708966
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase II study evaluating the feasibility of a 5-week cycle of S-1 plus irinotecan (IRIS) in patients with advanced and recurrent colorectal cancer.
    Hata T; Fukunaga M; Murata K; Uemura Y; Fukuzaki T; Ota H; Ohue M; Ohnishi T; Tanaka N; Takemasa I; Mizushima T; Ikeda M; Yamamoto H; Sekimoto M; Nezu R; Doki Y; Mori M
    Cancer Chemother Pharmacol; 2013 Jun; 71(6):1657-63. PubMed ID: 23543294
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Irinotecan plus oral S-1 in patients with advanced colorectal cancer--biweekly IRIS regimen].
    Komatsu Y; Yuki S; Tateyama M; Kudo M; Asaka M
    Gan To Kagaku Ryoho; 2006 Jun; 33 Suppl 1():131-4. PubMed ID: 16897988
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II study of combination therapy with S-1 and irinotecan in patients with advanced colorectal cancer.
    Goto A; Yamada Y; Yasui H; Kato K; Hamaguchi T; Muro K; Shimada Y; Shirao K
    Ann Oncol; 2006 Jun; 17(6):968-73. PubMed ID: 16603600
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of irinotecan plus S-1 (IRIS) therapy to treat advanced/recurrent colorectal cancer.
    Higashi D; Egawa Y; Hirano Y; Hirano K; Miyake T; Takahashi H; Uwatoko S; Abe S; Yamamoto S; Mikami K; Futami K; Maekawa T; Inoue R; Miyazaki M
    Anticancer Res; 2014 Aug; 34(8):4595-9. PubMed ID: 25075105
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Panitumumab in combination with irinotecan plus S-1 (IRIS) as second-line therapy for metastatic colorectal cancer.
    Takaoka T; Kimura T; Shimoyama R; Kawamoto S; Sakamoto K; Goda F; Miyamoto H; Negoro Y; Tsuji A; Yoshizaki K; Goji T; Kitamura S; Yano H; Okamoto K; Kimura M; Okahisa T; Muguruma N; Niitsu Y; Takayama T
    Cancer Chemother Pharmacol; 2016 Aug; 78(2):397-403. PubMed ID: 27342247
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II clinical trial of metronomic chemotherapy with combined irinotecan and tegafur-gimeracil-oteracil potassium in metastatic and recurrent breast cancer.
    Otsuka H; Fujii T; Toh U; Iwakuma N; Takahashi R; Mishima M; Takenaka M; Kakuma T; Tanaka M; Shirouzu K
    Breast Cancer; 2015 Jul; 22(4):335-42. PubMed ID: 23827973
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II study of irinotecan/S-1 combination chemotherapy for patients with oxaliplatin-refractory colorectal cancer.
    Oh SY; Ju YT; Choi SK; Ha CY; Lee WS; Kim HG; Lee GW; Kwon HC; Kang JH
    Invest New Drugs; 2011 Oct; 29(5):1050-6. PubMed ID: 20238142
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Phase II Trial of Combined Chemotherapy with Oral S-1 and 24-Hour Infusions of Irinotecan plus Bevacizumab in Patients with Metastatic Colorectal Cancer.
    Sadahiro S; Suzuki T; Tanaka A; Okada K; Saito G; Kamijo A
    Oncology; 2015; 88(6):353-9. PubMed ID: 25592116
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase II study of combination therapy with irinotecan and S-1 (IRIS) in patients with advanced colorectal cancer.
    Shiozawa M; Akaike M; Sugano N; Tsuchida K; Yamamoto N; Morinaga S
    Cancer Chemother Pharmacol; 2010 Oct; 66(5):987-92. PubMed ID: 20623226
    [TBL] [Abstract][Full Text] [Related]  

  • 13. S-1 and irinotecan plus bevacizumab as second-line chemotherapy for patients with oxaliplatin-refractory metastatic colorectal cancer: a multicenter phase II study in Japan (KSCC1102).
    Miyamoto Y; Tsuji A; Tanioka H; Maekawa S; Kawanaka H; Kitazono M; Oki E; Emi Y; Murakami H; Ogata Y; Saeki H; Shimokawa M; Natsugoe S; Akagi Y; Baba H; Maehara Y
    Int J Clin Oncol; 2016 Aug; 21(4):705-712. PubMed ID: 26746689
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I/II study of a 3-week cycle of irinotecan and S-1 in patients with advanced colorectal cancer.
    Kusaba H; Esaki T; Futami K; Tanaka S; Fujishima H; Mitsugi K; Sakai K; Ariyama H; Tanaka R; Kinugawa N; Ueki T; Mibu R; Baba E; Nakano S; Akashi K
    Cancer Sci; 2010 Dec; 101(12):2591-5. PubMed ID: 21077997
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II study of S-1 combined with irinotecan (CPT-11) in patients with advanced colorectal cancer.
    Tsunoda A; Yasuda N; Nakao K; Narita K; Watanabe M; Matsui N; Kusano M
    Oncology; 2009; 77(3-4):192-6. PubMed ID: 19729976
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Multicenter Feasibility Study with S-1, Oxaliplatin and Oral Leucovorin (SOL) for the Patients with Untreated Metastatic Colorectal Cancer: The Result of Final Analysis.
    Lu M; Wang Y; Liu W; Bai C; Xu J; Shen L
    Hepatogastroenterology; 2014 Jun; 61(132):1018-23. PubMed ID: 26158159
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A feasibility study of UFT/LV and irinotecan (TEGAFIRI) in advanced or metastatic colorectal cancer: Osaka Gastrointestinal Cancer Chemotherapy Study Group (OGSG) PROG 0304.
    Ishida H; Miyake Y; Fukunaga M; Watanabe Y; Kato T; Takemoto H; Furukawa H
    Jpn J Clin Oncol; 2009 Sep; 39(9):601-5. PubMed ID: 19535386
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term results of a phase II study of S-1 plus irinotecan in metastatic colorectal cancer.
    Iwasa S; Yamada Y; Kato K; Goto A; Honma Y; Hamaguchi T; Shimada Y
    Anticancer Res; 2012 Sep; 32(9):4157-61. PubMed ID: 22993378
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II study of docetaxel and S-1 combination therapy for advanced or recurrent gastric cancer.
    Yoshida K; Ninomiya M; Takakura N; Hirabayashi N; Takiyama W; Sato Y; Todo S; Terashima M; Gotoh M; Sakamoto J; Nishiyama M
    Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3402-7. PubMed ID: 16740764
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II study of oral S-1 plus irinotecan in patients with advanced colorectal cancer: Hokkaido Gastrointestinal Cancer Study Group HGCSG0302.
    Komatsu Y; Yuuki S; Fuse N; Takei M; Kato T; Miyagishima T; Kudo M; Kunieda Y; Tateyama M; Wakahama O; Meguro T; Ohizumi H; Watanabe M; Akita H; Sakata Y; Asaka M
    Jpn J Clin Oncol; 2005 Feb; 35(2):88-9. PubMed ID: 15709093
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.